Journal of Microbiology and Biotechnology

The Korean Society for Microbiology and Biotechnology (한국미생물·생명공학회)
권호 표지

Optimization and Validation of a Virus Filtration Process for Efficient Removal of Viruses from Urokinase Solution Prepared from Human Urine

  • Kim, In-Seop (Department of Biological Sciences, College of Natural Sciences, Hannam University) ;
  • Choi, Yong-Woon (Central Research Center, Green Cross Plasma Derivatives Company) ;
  • Lee, Sung-Rae (Central Research Center, Green Cross Plasma Derivatives Company)
  • Published : 2004.02.01
Download PDF
⟨ Previous Next ⟩

Abstract

Urokinase is an enzyme with fibrinolytic activity (plasminogen activator) isolated from fresh urine of healthy men. Viral safety is an important prerequisite for clinical preparation of the protein from urine. In order to increase the viral safety of a high purity urokinase in regard to non-enveloped viruses, a virus removal process using a novel polyvinylidene fluoride membrane filter (Viresolve NFP) has been optimized. Urokinase was able to pass through the filter with recoveries of 95% in the production scale process. No substantial changes were observed in physical and biochemical characteristics of the filtered urokinase in comparison with those of the enzyme before filtration. A 47-mm disk membrane filter was used to simulate the process performance of the production scale cartridges and tested if it could remove several experimental model viruses for human pathogenic viruses, including porcine parvovirus (PPV), human hepatitis A virus (HAV), murine encephalomyocarditis virus (EMCV), bovine viral diarrhoea virus (BVDV), and bovine herpes virus (BHV). Non-enveloped viruses (PPV, HAV, and EMCV) as well as enveloped viruses (BVDV and BHV) were completely removed during filtration. The log reduction factors achieved were $\geq$4.86 for PPV, $\geq$4.60 for HAV, $\geq$6.87 for EMCV, $\geq$4.60 for BVDV, and $\geq$5.44 for BHV. These results indicate that the virus filtration process successfully improved the viral safety of the final products.

Keywords

References

  1. Andrewes, C. 1989. Andrewes Viruses of Vertebrates, pp. 120-145. Balliere Tindal, London, U.K
  2. Arahana, H. 2001. Viral clearance strategies for biopharmaceutical safety. Part 2: Filtration for viral clearance. Biol. Pharm. February: 32-43
  3. Aranha-Creado, H., J. Peterson, and P. Y. Huang. 1998. Clearance of murine leukaemia virus from monoclonal antibody solutions by a hydrophilic PVDF microporous membrane filter. Biologicals 26: 167-172
  4. Aranha-Creado, H., K. Oshima, S. Jafari, G. Honward, Jr. and H. Brandwein. 1997. Virus retention by a hydrophilic triple-layer PVDF microporous membrane filter. PDA J. Pharm. Sci. Technol. 51: 119-124
  5. Badmington F., R. Wilkins, M. Payne, and E. S. Honig. 1995. Vmax testing for practical microfiltration train scaleup in biopharmaceutical processing. Pharm. Technol. September: 64-76
  6. Bennion, D. W., L. J. Wright, R. A. Watt, A. A. Whiting, and J. F. Carlquist. 1998. Optimal recovery of cytomegalovirus from urine as a function of specimen preparation. Diagn. Microbiol. Infect. Dis. 31: 337-342
  7. Borovec, S., C. Broumis, W. Adcock, R. Fang, and E. Uren. 1998. Inactivation kinetics of model and relevant bloodborne viruses by treatment with sodium hydroxide and heat. Biologicals 26: 237-244
  8. Cao, X. J., J. H. Zhou, Z. H. Huang, X. Y. Wu, and B. K. Hur. 2002. Preparation of high-purity urokinase using single-step hydrophobic interaction chromatography with p-aminobenzamidine ligand. J. Microbiol. Biotechnol. 12: 196-203
  9. Coulepis, A. G., S. A. Locarnini, N. I. Lehmann, and I. D. Gust. 1980. Detection of hepatitis A virus in the feces of patients with naturally acquired infections. J. Infect. Dis. 141: 151-156
  10. Eibl, J., N. Barrett, T. Hämmerle, and F. Dorner. 1996. Nanofiltration of immunoglobulin with 35-nm filters fails to remove substantial amounts of HCV. Biologicals 24: 285- 287
  11. Graf, E. G., E. Jander, A. West, H. Pora, and H. Aranha- Creado. 1999. Virus removal by filtration. Dev. Biol. Stand. 99: 84-89
  12. Kim, I. S., H. G. Eo, C. E. Chang, and S. Lee. 2000. Partitioning and inactivation of viruses by cold ethanol fractionation and pasteurization during manufacture of albumin from human plasma. J. Microbiol. Biotechnol. 10: 858-864
  13. Kim, I. S., Y. W. Choi, H. S. Woo, C. E. Chang, and S. Lee. 2000. Solvent/detergent inactivation and chromatographic removal of human immunodeficiency virus during the manufacturing of a high purity antihemophilic factor VIII concentrate. J. Microbiol. 38: 187-191
  14. Kim, I. S., Y. W. Choi, S. R. Lee, H. B. Cho, H. G. Eo, H. S. Woo, C. E. Chang, and S. Lee. 2001. Improvement of virus safety of a human intravenous immunoglobulin by low pH incubation. J. Microbiol. Biotechnol. 11: 619-627
  15. Kim, I. S., Y. W. Choi, S. R. Lee, H. S. Woo, and S. Lee. 2001. Removal and inactivation of viruses during manufacture of a high purity antihemophilic factor VIII concentrate from human plasma. J. Microbiol. Biotechnol. 11: 497-503
  16. Kim, I. S., Y. W. Choi, S. R. Lee, M. S. Lee, K. H. Huh, and S. Lee. 2001. Removal and inactivation of hepatitis A virus during manufacture of a high purity antihemophilic factor VIII concentrate from human plasma. J. Microbiol. 39: 67- 73
  17. Levy, J. A., H. Fraenkel-Conrat, and R. A. Owens. 1994. Virology, pp. 153-160. 3rd ed. Prentice Hall, Englewood Cliffs, NJ, U.S.A
  18. Melchers, W. J., R. Schift, E. Stolz, J. Lindeman, and W. G. Quint. 1989. Human papillomavirus detection in urine samples from male patients by the polymerase chain reaction. J. Clin. Microbiol. 27: 1711-1714
  19. Mosley, J. W. and J. Rakela. 1999. Foundling viruses and transfusion medicine. Transfusion 39: 1041-1044
  20. Oshima, K. H., T. T. Evans-strickfaden, and A. K. Highsmith. 1998. Comparison of filtration properties of hepatitis B virus, hepatitis C virus and simian virus 40 using a polyvinylidene fluoride membrane filter. Vox Sang. 75: 181-188
  21. Oshima, K. H., T. T. Evans-strickfaden, A. K. Highsmith, and E. W. Ades. 1998. The use of a microporus polyvinylidene fluoride (PVDF) membrane filter to separate contaminating viral particles from biologically important proteins. Biologicals 24: 137-145
  22. Prowse, C., C. A. Ludlam, and P. L. Yap. 1997. Human parvovirus B19 and blood products. Vox Sang. 72: 1-10
  23. Roberts, P. 1996. Virus safety of plasma products. Rev. Med. Virol. 6: 25-38
  24. Roberts, P. 1997. Efficient removal of viruses by a novel polyvinylidene fluoride membrane filter. J. Virol. Methods 65: 27-31
  25. Schalasta, G., M. Eggers, M. Schmid, and G. Enders. 2000. Analysis of human cytomegalovirus DNA in urines of newborns and infants by means of a new ultrarapid real-time PCR-system. J. Clin. Virol. 19: 175-185
  26. Sherry, S. 1987. Thrombolytic therapy in acute myocardial infarction. A perspective. Drugs 33(Suppl 3): 1-12
  27. Troccoli, N., J. Mclver, A. Losikoff, and J. Poiley. 1998. Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration. Biologicals 26: 321-329
  28. Yoon, S. J., M. A. Yu, G. S. Sim, S. T. Kwon, J. K. Hwang, J. K. Shin, I. K. Yeo, and Y. R. Pyun. 2002. Screening and characterization of microorganisms with fibrinolytic activity from fermented foods. J. Microbiol. Biotechnol. 12: 649- 656